Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Jul 18, 2022

SELL
$3.17 - $6.17 $132,189 - $257,289
-41,700 Closed
0 $0
Q1 2022

May 02, 2022

SELL
$4.16 - $13.72 $832 - $2,744
-200 Reduced 0.48%
41,700 $225,000
Q4 2021

Feb 10, 2022

BUY
$10.83 - $18.41 $453,777 - $771,379
41,900 New
41,900 $566,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $242M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Davenport & CO LLC Portfolio

Follow Davenport & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Davenport & CO LLC with notifications on news.